Synthetic cannabinoid (SCRA)
Narcotic: named in scheduleMMB-FUBINACAMMB-FUBINACA (AMB-FUBINACA, FUB-AMB)
methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
Aliases.AMB-FUBINACA · FUB-AMB
The cause of the Brooklyn "zombie" outbreak (July 2016; 33 hospitalisations, NEJM 2017).
Updated on
Level of detail
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Identifiers
- Formula
- C₂₀H₂₁FN₃O₃
- Molar mass
- 386.40 g·mol⁻¹
- CAS
- 1715016-75-3
- PubChem CID
- 118791037
- First described
- 2009
- Origin
- Pfizer patent WO 2009/106980 (never marketed)
- InChIKey
- JFZAQUNZQZASBL-AWEZNQCLSA-N
In plain terms
MMB-FUBINACA is known for having caused the Brooklyn "zombie" outbreak in July 2016 - 33 people hospitalised on the same day in a state resembling catatonia. Highly dangerous.
Receptors and activity
- CB1EC50 ≈ 0,54 nMAgonist
- CB2Agonist
- Agonist
- Partial agonist
- Antagonist
- Modulator
- Inverse agonist
Hover over a row for the precise value (Ki, EC50…)
Subjective signature
Hover over an axis to read its definition.
- Calm15
- Clarity10
- Sleep55
- Appetite40
- High99
Editorial estimate, not clinical.
Pharmacology
MMB-FUBINACA (= AMB-FUBINACA = FUB-AMB) - an indazole-3-carboxamide with an L-valine methyl ester head and a 4-fluorobenzyl tail. Derived from Pfizer patent WO 2009/106980. Banister et al. (ACS Chem Neurosci 2016): Ki = 10.04 nM, EC50 = 0.54 nM (β-arrestin). Brooklyn outbreak of 12 July 2016 - 33 simultaneous hospitalisations with the characteristic "zombie" presentation (blank stare, slow movements, mutism) documented by Adams et al. (NEJM 2017, PMID 29262413). France: **Decree of 31 March 2017** (NOR AFSP1710288A). CND **62/6** (March 2019) → Schedule II of the 1971 Convention.
Origin (pharmaceutical research → illicit market)
An indazole-3-carboxamide with an L-valine methyl ester head and a 4-fluorobenzyl tail
Legal framework
International
1971 Schedule II
CND 62/6 (Mar 2019)
European Union
Décision Conseil (UE) 2019/1525
France
Annexe IV : listé
Arrêté 31 mars 2017, NOR AFSP1710288A
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Structural classification
- Class
- Synthetic cannabinoid (SCRA)
- Origin
- Pfizer patent WO 2009/106980 (never marketed)
- Status
- Narcotic: named in schedule
References
- 1.Adams · NEJM 2017PMID 29262413
- 2.Banister · ACS Chem Neurosci 2016PMID 27421060
Structured data
- InChIKey
- JFZAQUNZQZASBL-AWEZNQCLSA-N
- SMILES
- CC(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3=CC=C(C=C3)F
- Formula
- C20H21FN3O3
- Molar mass
- 386.40 g·mol⁻¹
- CAS
- 1715016-75-3
- PubChem CID
- 118791037
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.